Figure 4.
Detection of free and complexed antibodies in patients with acquired TTP treated with rituximab and in remission for at least 1 year. Plasma samples from patients (1–10) treated with rituximab during the acute event were analyzed by ELISA for the presence of free and complexed IgG anti-ADAMTS13 antibodies during clinical remission. The duration of remission (y=years) is shown for each patient. ADAMTS13-specific immune complexes were mainly of subclass IgG4. IC: immune complexes.